ABSTRACT According to the annual report of Gambro, there were about 1,153,080 ESRD ( End Stage Renal Disease ) in the world-wide market; meanwhile, there were 294,050 ESRD in US market, 244,450 in European market, 206,000 in Japanese market. From Brooke Hollis¡¦ research report ( 1998 ), it indicated about 34% of Dialysis Center belonging to Dialysis Provider in the US market, and it forecasted the percentage should be increased up to 71% until 2001. Actually, there is about 66% of Dialysis Center hold by Dialysis Provider in the US market in 2001. In the Taiwan market, there were 31,106 ESRD ( 1999 ), depending on the statistic from Taiwan Society of Nephrology. The total expense of the dialysis therapy was about 13.37 billion in 1998. It increased about 14% per year, therefore, it expanded to 15.22 billion in 1999, then up to 17.57 billion in 2000. Since the fast growth of the Dialysis market in Taiwan and its potential, some of famous global industries, such as Fresenius, Gambro, and Baxter has get involved in Taiwan market and has directly entered the competition in the management of channel. Originally, Dialysis Agent was prototypical style for the Multiple-national industry in the Dialysis Market to develop cross-aboard. But, the competition type has became to be Dialysis Provider. Enfield Medical Inc. is one of successful companies during the development. During the thesis, the writer is interested in the strategy changing and developing, and make the research to analyze and to conclude the changing and the developing strategy of dialysis Industry.